source · text/csv
source_14eda58680674192
sha256 2185a1048294e3a2137941246bfc5cde328ea22f04224f7d371cd534d0bcf2fd
by researka:v2 · 2026-06-07 01:44:54.043382+04:00
study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
metadata
{
"researka_object_type": "publication_sidecar",
"researka_publication_id": "3591803f-c88e-47e8-a088-a212f55ad36d",
"researka_submission_id": "e9ee22f6-f8be-49ba-b6ab-40a834ec19cb",
"sidecar_name": "evidence_table.csv",
"sidecar_url": "https://api.researka.org/publications/3591803f-c88e-47e8-a088-a212f55ad36d/sidecars/evidence_table.csv"
}